title: Donor-derived metastatic melanoma in a liver transplant recipient established by DNA fingerprinting.
abstract: Metastatic melanoma is a donor-derived malignancy that has rarely been reported in liver allograft recipients. We present a case of a transmitted donor-derived melanoma to a liver allograft recipient in whom the diagnosis was established by polymerase chain reaction-based DNA fingerprinting. A 52-year-old African-American man underwent a successful orthotropic liver transplant for alcohol-induced cirrhosis. One year after the orthotropic liver transplant, he presented at our institution with diffuse abdominal pain, and a computed tomography scan of the abdomen and chest showed innumerable masses diffusely involving the liver and multiple subcutaneous nodules in the abdominal and chest wall. A liver biopsy confirmed the diagnosis of metastatic melanoma. The origin of melanoma was traced to the donor by DNA fingerprinting of the native liver, the donor liver, and the donor gallbladder. Chemotherapy was initiated with temozolomide (75 mg/m² daily) and thalidomide (50 mg daily), to which he responded within 8 weeks with radiologic improvement in metastatic lesions. Tacrolimus was switched to sirolimus because of renal insufficiency as well as reported effectiveness against melanoma. Our patient survived for 9 months after the diagnosis of metastatic melanoma. He ultimately died of brain metastases. Donor-derived metastatic melanoma is a rare cancer with the highest transmission and mortality rates, which requires better recognition. Prompt diagnosis of donor-derived melanoma is critical and can be achieved reliably with polymerase chain reaction-based DNA analysis. Management options after diagnosis include de-escalation of immunosuppression, with or without urgent organ removal or retransplant. The roles of chemotherapy, immunotherapy, and radiotherapy require further study.
authors.affiliation: Department of Gastroenterology, University of Tennessee Health Science Center, Memphis, TN, USA.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Bilal
authors.forename: James D
authors.initials: JD
authors.lastname: Eason
authors.forename: Kanak
authors.initials: K
authors.lastname: Das
authors.forename: Pamela B
authors.initials: PB
authors.lastname: Sylvestre
authors.forename: Amanda G
authors.initials: AG
authors.lastname: Dean
authors.forename: Jason M
authors.initials: JM
authors.lastname: Vanatta
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D001706:Biopsy; D001932:Brain Neoplasms / Q000235:genetics / Q000556:secondary; D016172:DNA Fingerprinting; D018450:Disease Progression; D017809:Fatal Outcome; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000235:genetics* / Q000556:secondary* / Q000628:therapy; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000235:genetics* / Q000556:secondary* / Q000628:therapy; D008875:Middle Aged; D011237:Predictive Value of Tests; D012878:Skin Neoplasms / Q000235:genetics* / Q000473:pathology*; D013997:Time Factors; D014019:Tissue Donors; D014057:Tomography, X-Ray Computed
chemical_list: D014408:Biomarkers, Tumor; D007166:Immunosuppressive Agents